R
Roberto Carlesi
Researcher at Eli Lilly and Company
Publications - 11
Citations - 2193
Roberto Carlesi is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Ramucirumab & Progression-free survival. The author has an hindex of 7, co-authored 11 publications receiving 1694 citations.
Papers
More filters
Journal ArticleDOI
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke,Kei Muro,Eric Van Cutsem,Sang Cheul Oh,György Bodoky,Yasuhiro Shimada,Shuichi Hironaka,Naotoshi Sugimoto,Oleg Lipatov,Tae You Kim,David Cunningham,Philippe Rougier,Yoshito Komatsu,Jaffer A. Ajani,Michael Emig,Roberto Carlesi,David Ferry,Kumari Chandrawansa,Jonathan D. Schwartz,Atsushi Ohtsu +19 more
TL;DR: The combination of ramucirumab with pac litaxel significantly increases overall survival compared with placebo plus paclitaxel, and could be regarded as a new standard second-line treatment for patients with advanced gastric cancer.
Journal ArticleDOI
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Charles S. Fuchs,Kohei Shitara,Maria Di Bartolomeo,Sara Lonardi,Salah-Eddin Al-Batran,Eric Van Cutsem,David H. Ilson,Maria Alsina,Ian Chau,Jill Lacy,Michel Ducreux,Michel Ducreux,Guillermo Mendez,Alejandro Molina Alavez,Daisuke Takahari,Wasat Mansoor,Peter C. Enzinger,Vera Gorbounova,Zev A. Wainberg,Susanna Hegewisch-Becker,David Ferry,Ji Lin,Roberto Carlesi,Mayukh Das,Manish A. Shah,Manish A. Shah,Alexander Luft,Nina A. Karaseva,Rubén Dario Kowalyszyn,Carlos Alberto Hernandez,Tibor Csoszi,Ferdinando De Vita,Per Pfeiffer,Naotoshi Sugimoto,Judit Kocsis,Andràs Csilla,György Bodoky,Georgina Garnica Jaliffe,Svetlana Protsenko,A Madi,Elzbieta Wojcik,Baruch Brenner,Gunnar Folprecht,Tomasz Sarosiek,Katriina Peltola,Peter Bono,Hubert Ayala,Giuseppe Aprile,Cardellino Giovanni Gerardo,Fidel David Huitzil Melendez,Alfredo Falcone,Francesco Di Costanzo,Moustapha Tehfe,Laurent Mineur,Pilar Garcia Alfonso,Radka Obermannova,Hélène Senellart,Russell D. Petty,Leslie Samuel,Peter Istvan Acs,Maen A. Hussein,Marina N. Nechaeva,F.L.G. Erdkamp,Elizabeth Won,Johanna C. Bendell,Javier Gallego Plazas,Sylvie Lorenzen,Bohuslav Melichar,Miguel Angel Escudero,Denis Pezet,Jean-Marc Phelip,Diego Lucas Kaen,James A. Jr Reeves,Federico Longo Munoz,Srinivasan Madhusudan,Carlo Barone,Luis Fein,Angel Gomez Villanueva,Mohamed Hebbar,Jana Prausová,Laura Visa Turmo,Joana Vidal Barrull,Mette Karen Yilmaz,Alex Beny,H.M.W. Van Laarhoven,Brian Anthony DiCarlo,Taito Esaki,Kazumasa Fujitani,Karen Geboes,Ravit Geva,Shigenori Kadowaki,Stephen Leong,Nozomu Machida,Moses Sundar Raj,Francisco Javier Ramirez Godinez,Agnes Ruzsa,Hugo Ford,William E. Lawler,Nicolas Robert Maisey,Jiri Petera,Einat Shacham-Shmueli,Isabelle Sinapi,Kensei Yamaguchi,Hiroki Hara,J.T. Beck,Maria Błasińska-Morawiec,Ricardo Villalobos Valencia,Thierry Alcindor,Madhuri Bajaj,Scott M. Berry,Christina Maria Gomez,Daniel Dammrich,Ravindranath Patel,Julien Taieb,A.J. Ten Tije,Ronald L. Burkes,Fernando Cabanillas,Irfan Firdaus,Cynthia Coo Chua,Shuichi Hironaka,Ralf-Dieter Hofheinz,Howard J. Lim,Marianne Nordsmark,Bela Piko,Udit Verma,Jonathan Wadsley,Seigo Yukisawa,Francisco Gutiérrez Delgado,Crystal S. Denlinger,Raija Kallio,Joanna Pikiel,Joanna Wojcik-Tomaszewska,Christine Brezden-Masley,Raymond Jang,Jana Pribylova,Daisuke Sakai,Maria Alejandra Bartoli,Annemieke Cats,M.I. Grootscholten,Robert Andrew Dichmann,Hugo Hool,Walid Shaib,Akihito Tsuji,Marc Van den Eynde,Hector Velez-Cortez,Timothy R. Asmis +145 more
TL;DR: The addition of ramucirumab, a VEGFR-2 antagonist monoclonal antibody, to first-line chemotherapy improves outcomes in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Journal ArticleDOI
RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE).
Hansjochen Wilke,Eric Van Cutsem,Sang Cheul Oh,György Bodoky,Yasuhiro Shimada,Shuichi Hironaka,Naotoshi Sugimoto,Oleg Lipatov,Tae-You Kim,David Cunningham,Atsushi Ohtsu,Philippe Rougier,Michael Emig,Roberto Carlesi,Kumari Chandrawansa,Kei Muro +15 more
TL;DR: In this paper, the efficacy and safety of PTX +/- RAM were evaluated in patients with metastatic GEJ or gastric adenocarcinoma who had disease progression on or within 4 months after first-line platinum-and fluoropyrimidine-based combination therapy.
Journal ArticleDOI
Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.
Li-Tzong Chen,Do Youn Oh,Min Hee Ryu,Kun-Huei Yeh,Winnie Yeo,Roberto Carlesi,Rebecca Cheng,Jong Seok Kim,Mauro Orlando,Yoon-Koo Kang +9 more
TL;DR: Overall, agents that specifically target the vascular endothelial growth factor ligand or receptor have better safety profile compared to multi-target tyrosine kinase inhibitors.
Journal ArticleDOI
Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer
Kei Muro,Sang Cheul Oh,Yasuhiro Shimada,Keun Wook Lee,Chia Jui Yen,Yee Chao,Yee Chao,Jae Yong Cho,Rebecca Cheng,Roberto Carlesi,Kumari Chandrawansa,Mauro Orlando,Atsushi Ohtsu +12 more
TL;DR: A subgroup analysis of East Asians in the positive study RAINBOW is presented, finding that East Asians with higher gastric cancer incidence and mortality rates than other regions are likely to be at higher risk of disease.